JAZZ
USDJazz Pharmaceuticals plc Common Stock (Ireland)
Цена в режиме реального времени
График цен
Ключевые показатели
Рыночные показатели
Открытие
$110.945
Максимум
$111.450
Минимум
$109.480
Объем
0.48M
Фундаментальные показатели компании
Рыночная капитализация
6.6B
Отрасль
Биотехнология
Страна
Ireland
Статистические данные торговли
Средний объем
1.27M
Биржа
NMS
Валюта
USD
52-недельный диапазон
Связанные новости
Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $202 Price Target
Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals with a Buy and maintains $202 price target.
Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug...
Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced late-breaking Phase 4 data evaluating treatment benefits of Xywav® (calcium, magnesium,...
Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $202 Price Target
Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals with a Buy and maintains $202 price target.
Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive results from the Phase 3 IMforte study of Zepzelca® (lurbinectedin) in combination...
Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced long-term data, including the first report of median overall survival (OS) from the Phase 2...
Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that nineteen abstracts, including eleven late-breaking abstracts will be presented at SLEEP...
Связанные акции
Оставаться в курсе
Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.